

Arden and Greater East Midlands Commissioning Support Unit in association with  
Lincolnshire Clinical Commissioning Groups, Lincolnshire Community Health Services,  
United Lincolnshire Hospitals Trust and Lincolnshire Partnership Foundation Trust

## Lincolnshire *PACE* Shorts

Summary of PACEF decisions from November 2015

For further details see *PACE Bulletin* Volume 9 No 21 (December 2015)

Drug	Indication(s)	Traffic Light and <i>Joint Formulary</i> Status
Dipipanone 10mg/cyclizine 30mg tablets (previously <i>Diconal</i> )	For moderate to severe pain	<b>RED-RED</b> The Controlled Drug Accountable Officer and Lincolnshire Police have requested that all prescribing should cease to mitigate the risk of drug misuse and diversion. Oral morphine or even oral oxycodone (for those intolerant of morphine) are preferred.
Empagliflozin/metformin tablets 5mg/ 850mg, 5mg/1000mg, 12.5mg/850mg and 12.5mg/1000mg ( <i>Synjardy</i> ) (Boehringer Ingelheim)	For the treatment of type 2 diabetes	<b>GREEN</b> Approved for inclusion in the <i>Lincolnshire Joint Formulary</i>
Insulin glargine 100 units/ml injection ( <i>Abasaglar</i> ) cartridges and KwikPen (Eli Lilly and Company Ltd)	Treatment of diabetes mellitus in adults, adolescents and children aged 2 years and above.	<b>GREEN</b> Approved for inclusion in the <i>Lincolnshire Joint Formulary</i>
Insulin glargine 300units/ml injection (Toujeo) (Sanofi)	Treatment of diabetes mellitus in adults	<b>AMBER</b> without shared care Approved for inclusion in the <i>Lincolnshire Joint Formulary</i> . Should only be initiated on the advice of a diabetologist or a GP with a specialist interest in diabetes for those experiencing an unacceptable frequency and/or severity of nocturnal hypoglycaemia or attempting to achieve better hypoglycaemia control during treatment with established insulins.
Levothyroxine sodium 25, 50 and 100 microgram tablets	Hypothyroidism	<b>GREEN</b> Included in the <i>Lincolnshire Joint Formulary</i> .
Liothyronine 20microgram tablets	Hypothyroidism	<b>AMBER</b> without shared care. For specialist initiation only. Included in the <i>Lincolnshire Joint Formulary</i> .
Lithium carbonate Essential Pharma 250mg tablet (Essential Pharma Ltd)	Treatment and prophylaxis of mania, bipolar disorder, recurrent depression, aggressive or self-harming behaviour	<b>AMBER</b> Included in the <i>Lincolnshire Joint Formulary</i> .
Midodrine hydrochloride 2.5mg and 5mg tablets ( <i>Bramox</i> ) (Brancaster Pharma)	For the treatment of severe orthostatic hypotension due to autonomic dysfunction when corrective factors have been ruled out and other forms of treatment are inadequate.	<b>AMBER</b> with shared care Included in the <i>Lincolnshire Joint Formulary</i> for this indication.

Tafluprost 15mcg/timolol 5mg per ml preservative-free single use eye drops ( <i>Taptiqom</i> ) (Santen)	For the treatment of ocular hypertension or open-angle glaucoma insufficiently responsive to beta-blockers (BBs) or prostaglandin analogues (PGA) alone.	AMBER without shared care. Approved for inclusion in the <i>Lincolnshire Joint Formulary</i> . Preferred where a PGA/BB preservative-free preparation is indicated.
---	--	---

**RED-RED:** This signifies that a product is **not recommended** for prescribing in **either** primary or secondary care. All new products are classified as RED-RED pending assessment by PACEF.

**RED:** This signifies that a product has been approved for use within secondary care, tertiary care or a primary care hosted specialist service only and **should not be routinely prescribed in primary care**. RED drugs may be used within ULHT or LPFT subject to approval for use within each Trust. ULHT and LPFT reserve the right to determine whether or not RED drugs will be used within their Trusts. RED classification does not automatically signify that a drug will be available within secondary/tertiary care.

**AMBER:** This signifies that a drug has been approved for use in primary care **subject to specialist initiation; a shared care guideline (SCG) may also be required**. The main purpose of the SCG will be to clearly define both specialist and GP responsibilities. Not all AMBER drugs that require SCGs are currently covered by formal documents; PACEF are working to rectify this.

**GREEN:** This signifies a product that is **approved for initiation in either primary or secondary care**.

This bulletin has been created specifically to convey details of decisions taken at the Prescribing and Clinical Effectiveness Forum (PACEF) to all stakeholders across the Lincolnshire Healthcare Community in both primary and secondary care. Back issues of the *PACE Bulletin* and *PACE Shorts* are available through the PACEF website (<http://lincolnshire-pacef.nhs.uk>); follow the commissioning link to PACEF. Electronic copies of the *PACE Bulletin* are circulated to a wide readership via email. If you are not currently on our distribution list and wish to receive regular copies of PACEF publications please contact Sandra France on [sandra.france@gemcsu.nhs.uk](mailto:sandra.france@gemcsu.nhs.uk).

Google searching can be a quick and effective way of finding back numbers of the *PACE Bulletin* relevant to a specific topic of interest. Searchers are advised to use the official version of the *Bulletin* available from the PACEF website rather than depend on a potentially unreliable draft or variant found through Google or an alternative search engine.

The *Lincolnshire Joint Formulary* is available on line and is fully searchable; it can be accessed at [www.lincolnshirejointformulary.nhs.uk](http://www.lincolnshirejointformulary.nhs.uk)

**THIS DOCUMENT IS INTENDED FOR USE BY NHS HEALTHCARE PROFESSIONALS ONLY AND CANNOT BE USED FOR COMMERCIAL OR MARKETING PURPOSES WITHOUT PERMISSION**